Abstract
Background Strict travel restrictions have been imposed by numerous countries and have contributed to the large socioeconomic burden of the COVID-19 pandemic. The long quarantines that are applicable to contacts of cases may be excessive for travel policy.
Methods We developed an approach to evaluate imminent countrywide COVID-19 infections after 0–14-day quarantine and testing compared to travel ban, identifying the minimum quarantine duration for travelers from an origin country that did not increase the infection rate within the destination country as “sufficient.” We integrated prevalence, daily incidence, vaccine coverage, immunity, age demographics, and travel flow for 31 European countries.
Findings For the vast majority of country pairs, no testing, testing alone, or short quarantine were as effective as travel ban. Sufficient quarantines were predominantly influenced by disease prevalence and travel asymmetries. Analysis of the widespread variant of concern B.1.1.7 yielded similar results as for nonspecific viral incidence, whereas application to the heterogeneously distributed B.1.351variant required longer, more idiosyncratic quarantines. Adaptation to the European Union traffic-light risk stratification provided a simplified policy tool. Hospitalization rates were far more sensitive to countrywide vaccination coverage than to the duration of the travel quarantine or to the country of origin. Our analytical approach provides rigorous guidance for travel policy during early and late phases of pandemic disease.
Interpretation For nearly half of country pairs analysed, travel can be permitted in the absence of quarantine and testing without increasing short-term infection rates; for the majority of origin-destination pairs requiring controls, a three-day or shorter quarantine with RT-PCR or antigen testing on exit suffices. These travel quarantine durations are substantially shorter than those specified for traced contacts.
Funding EasyJet (JPT and APG), the Elihu endowment (JPT), the Burnett and Stender families’ endowment (APG), the Notsew Orm Sands Foundation (JPT and APG), and the National Institutes of Health (MCF).
Evidence before this study Evidence from early in the pandemic indicates that border closures at the epicenter slowed global dissemination of COVID-19. As community transmission became established in many nations, studies have suggested that the benefit of strict border closures in mitigating the transmission of disease from travellers diminished. Research for community settings has shown that testing later during quarantine, rather than upon entry to, can substantially shorten the duration of quarantine needed to reduce post-quarantine transmission.
Added value of this study No study has evaluated the effect of quarantine durations in the context of international travel, or for specific pairs of origin and destination countries. By accounting for prevalence, daily incidence, vaccine coverage, immunity, age demographics, and travel flow between countries, we quantified the contribution of travel towards imminent infections in the destination country under different quarantine and testing strategies. We developed a framework to identify quarantine and testing strategies that enable travel from specific origins without increasing their infection and hospitalization rates in the destinations. For travel between 31 European countries, our results demonstrate that there are often less burdensome quarantine and testing strategies that can serve as equivalent alternatives to strict border closure. Specifically, these sufficient quarantine durations are especially dependent on COVID-19 prevalence within the two countries and the asymmetry in the travel flow. Using data on variants of concern, we found whether a border control strategy is sufficient to limit variant spread depends strongly on their geographical distribution. Our framework is applicable not just for international travel, but can be applied at any spatial or population scale within which movement restrictions could feasibly be implemented.
Implications of all available evidence Travel quarantine and testing strategies can effectively mitigate importation and onward transmission within the country. Identifying these sufficient strategies can allow countries to permit travel with other countries, without risking an increase in their short-term infection rates. Once community transmission of disease or disease variants is ongoing, the long-term epidemic trend within the destination country is more apt to be determined by other disease control measures, e.g., contact tracing, vaccination, and non-pharmaceutical interventions. Together, travel quarantine and other related control measures can mitigate the risk of transmission between countries; limiting the threat of variants of concern.
Competing Interest Statement
JPT and APG declare the following competing interests: received funding from an airline company to conduct research on travel quarantine durations. CRW, AP, WC, and MCF declare no competing interest.
Funding Statement
JPT and APG gratefully acknowledge research funding from EasyJet. JPT gratefully acknowledges funding from the Elihu endowment and the Notsew Orm Sands Foundation. APG gratefully acknowledges funding from the Burnett and Stender families' endowment and the Notsew Orm Sands Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not required. No human subject data was used.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is referenced in the manuscript.
